LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 934

Search options

  1. Article ; Online: Professor Brian Leonard: Former Editor-in-Chief of Human Psychopharmacology.

    Baldwin, David S

    Human psychopharmacology

    2024  Volume 39, Issue 2, Page(s) e2894

    MeSH term(s) Humans ; Psychopharmacology
    Language English
    Publishing date 2024-02-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 632931-7
    ISSN 1099-1077 ; 0885-6222
    ISSN (online) 1099-1077
    ISSN 0885-6222
    DOI 10.1002/hup.2894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: 'Nico'-A lone voyager in Strange Seas.

    Baldwin, David S

    Human psychopharmacology

    2022  , Page(s) e2859

    Language English
    Publishing date 2022-12-08
    Publishing country England
    Document type Editorial
    ZDB-ID 632931-7
    ISSN 1099-1077 ; 0885-6222
    ISSN (online) 1099-1077
    ISSN 0885-6222
    DOI 10.1002/hup.2859
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Response to Fagiolini et al. (2023).

    Baldwin, David S / Masdrakis, Vasilios G

    Acta neuropsychiatrica

    2023  Volume 36, Issue 1, Page(s) 61–62

    MeSH term(s) Antidepressive Agents ; Selective Serotonin Reuptake Inhibitors
    Chemical Substances Antidepressive Agents ; Selective Serotonin Reuptake Inhibitors
    Language English
    Publishing date 2023-12-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 1154361-9
    ISSN 1601-5215 ; 0924-2708
    ISSN (online) 1601-5215
    ISSN 0924-2708
    DOI 10.1017/neu.2023.59
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3708: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The first patient to receive olanzapine: A recollection.

    Baldwin, David S

    Human psychopharmacology

    2021  Volume 36, Issue 6, Page(s) e2823

    MeSH term(s) Antipsychotic Agents/therapeutic use ; Benzodiazepines/therapeutic use ; Double-Blind Method ; Haloperidol ; Humans ; Olanzapine/therapeutic use
    Chemical Substances Antipsychotic Agents ; Benzodiazepines (12794-10-4) ; Haloperidol (J6292F8L3D) ; Olanzapine (N7U69T4SZR)
    Language English
    Publishing date 2021-10-26
    Publishing country England
    Document type Editorial
    ZDB-ID 632931-7
    ISSN 1099-1077 ; 0885-6222
    ISSN (online) 1099-1077
    ISSN 0885-6222
    DOI 10.1002/hup.2823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2192: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications.

    Baldwin, David S

    Addiction (Abingdon, England)

    2021  Volume 117, Issue 5, Page(s) 1472–1482

    Abstract: Benzodiazepines continue to be prescribed widely in the management of patients with insomnia or anxiety disorders, despite the availability and acceptability of alternative pharmacological and psychological treatments. Many patients will experience ... ...

    Abstract Benzodiazepines continue to be prescribed widely in the management of patients with insomnia or anxiety disorders, despite the availability and acceptability of alternative pharmacological and psychological treatments. Many patients will experience adverse effects during treatment and considerable distress when the dosage is reduced and stopped. Management of benzodiazepine withdrawal includes measures to prevent the development of dependence, careful attention to underlying medical conditions, medication consolidation and gradual dosage reduction, accompanying psychological interventions, occasional prescription of concomitant medication, and relapse prevention with on-going support to address psychosocial stressors. There are needs for easier patient access to services with refined expertise and for further research to optimise strategies for preventing dependence and facilitating withdrawal.
    MeSH term(s) Anti-Anxiety Agents/adverse effects ; Benzodiazepines/adverse effects ; Humans ; Hypnotics and Sedatives/adverse effects ; Substance Withdrawal Syndrome/drug therapy ; Substance Withdrawal Syndrome/etiology ; Substance-Related Disorders/therapy
    Chemical Substances Anti-Anxiety Agents ; Hypnotics and Sedatives ; Benzodiazepines (12794-10-4)
    Language English
    Publishing date 2021-10-28
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1141051-6
    ISSN 1360-0443 ; 0965-2140
    ISSN (online) 1360-0443
    ISSN 0965-2140
    DOI 10.1111/add.15695
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 551: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: Anxiety disorders

    Baldwin, David S. / Leonard, B. E.

    (Modern trends in pharmacopsychiatry ; 29)

    2013  

    Author's details volume ed. D.S. Baldwin ; B. E. Leonard
    Series title Modern trends in pharmacopsychiatry ; 29
    Collection
    Keywords Anxiety Disorders / therapy ; Angststörung
    Subject Pathologische Angst ; Pathologischer Angstzustand
    Language English
    Size IX, 183 S. : Ill., graph. Darst.
    Publisher Karger
    Publishing place Basel u.a.
    Publishing country Switzerland
    Document type Book
    Note Includes bibliographical references and index ; Preface : concerted efforts to improve the understanding and treatment of anxiety disorders / J. Angst, D.S. Baldwin -- On the nature of obsessions and compulsions / S. de Haan, E. Rietveld, D. Denys -- The origin of anxiety disorders : an evolutionary approach / L.E.W.G. Willers, N.C. Vulink, D. Denys, D.J. Stein -- Genetic factors in anxiety disorders / K. Domschke, E. Maron -- Neuroimaging in anxiety disorders / M. Fredrikson, V. Faria -- Potential neuroimmunological targets in the treatment of anxiety disorders / R. Hou, Z. Tang, D.S. Baldwin -- Anxiety and cardiovascular disease / S.J.C. Davies, C. Allgulander -- The early phases of anxiety disorders : from prevention to treatment / J. Vázquez-Bourgon, A. Herrán, J.L. Vázquez-Barquero -- Duration of untreated Illness and duration of illness in anxiety disorders : assessment and influence on outcome / A.C. Altamura, G. Camuri, B. Dell'Osso -- Pharmacotherapy of generalized anxiety disorder / C. Allgulander, D.S. Baldwin -- Pharmacological treatment of panic disorder / B. Bandelow, D.S. Baldwin, P. Zwanzger -- Pharmacological treatment of social anxiety disorder / V.G. Masdrakis, D. Turic, D.S. Baldwin -- Pharmacotherapy of posttraumatic stress disorder / A. Koller, D.J. Stein -- Evidence-based treatment pathways for translational studies in obsessive-compulsive disorders / N.A. Fineberg, S. Pallanti, S. Reghunandanan
    HBZ-ID HT017786024
    ISBN 978-3-318-02463-0 ; 9783318024647 ; 3-318-02463-5 ; 3318024643
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2013 A 2724 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: What is the role of a psychiatrist in the COVID-19 pandemic?

    Baldwin, David S

    Medicine (Abingdon, England : UK ed.)

    2020  Volume 48, Issue 11, Page(s) 685

    Keywords covid19
    Language English
    Publishing date 2020-09-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1238899-3
    ISSN 1357-3039
    ISSN 1357-3039
    DOI 10.1016/j.mpmed.2020.08.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Prevention of suicide by clozapine in mental disorders: systematic review.

    Masdrakis, Vasilios G / Baldwin, David S

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

    2023  Volume 69, Page(s) 4–23

    Abstract: Background: Previous research has investigated the efficacy of clozapine in reducing suicidality in patients with schizophrenia and schizoaffective disorder. We aimed to systematically review published evidence, including studies concerning clozapine ... ...

    Abstract Background: Previous research has investigated the efficacy of clozapine in reducing suicidality in patients with schizophrenia and schizoaffective disorder. We aimed to systematically review published evidence, including studies concerning clozapine administration to treat: (a) refractory suicidality in other mental disorders, including bipolar disorder and borderline and other personality disorders; and (b) refractory cases of non-suicidal self-injury.
    Method: We performed a PUBMED-search (last day: July 17, 2022) of English-language studies, combining the keywords "clozapine", "suicidality", and "suicide" with various psychopathological terms (e.g. "schizophrenia"). All duplications were eliminated.
    Results: Fifty-one studies were eligible for inclusion in the review. Most studies suggest a superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder, compared to other antipsychotics, or no antipsychotic therapy, which is not due to the close monitoring of patients for blood dyscrasias. No consensus exists as to whether other antipsychotic drugs share this effect. Discontinuation of clozapine is associated with increases in suicidality. Reductions in refractory suicidality/NSSI are observed in clozapine-treated patients with bipolar disorder or borderline personality disorder, but the evidence is limited. Potential biological underpinnings of the anti-suicide effect of clozapine include its unique profile of modulation of brain neurotransmitters; its non-selectivity for neurotransmitter receptors; specific genetic and hormonal factors; effects on neuroinflammation; and ability to elicit epileptiform activity.
    Conclusion: The superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder patients is well established. It may have a role in severe and refractory cases of suicidality and non-suicidal self-injury in patients with bipolar disorder or borderline personality disorder, but the level and quality of supporting evidence is limited.
    MeSH term(s) Humans ; Clozapine/therapeutic use ; Clozapine/pharmacology ; Suicide/psychology ; Mental Disorders/drug therapy ; Antipsychotic Agents/therapeutic use ; Schizophrenia/drug therapy
    Chemical Substances Clozapine (J60AR2IKIC) ; Antipsychotic Agents
    Language English
    Publishing date 2023-01-12
    Publishing country Netherlands
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 1082947-7
    ISSN 1873-7862 ; 0924-977X
    ISSN (online) 1873-7862
    ISSN 0924-977X
    DOI 10.1016/j.euroneuro.2022.12.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 630: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.

    Fagan, Harry A / Baldwin, David S

    Expert review of neurotherapeutics

    2023  Volume 23, Issue 6, Page(s) 535–548

    Abstract: Introduction: Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry. Current management consists of a range of pharmacological and psychological treatments. ... ...

    Abstract Introduction: Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry. Current management consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatments and novel anxiolytic drugs are being developed.
    Areas covered: In this review, the authors first discuss the diagnostic criteria and epidemiology of GAD. The effective pharmacological treatments for GAD and their tolerability are addressed. Current consensus guidelines for treatment of GAD are discussed, and maintenance treatment, the management of treatment resistance, and specific management of older adults and children/adolescents are considered. Finally, novel anxiolytics under development are discussed, with a focus on those which have entered clinical trials.
    Expert opinion: A range of effective treatments for GAD are available, particularly duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine. There is a limited evidence base to support the further pharmacological management of patients with GAD who have not responded to initial treatment. Although many novel anxiolytics have progressed to clinical trials, translation from animal models has been mostly unsuccessful. However, the potential of several compounds including certain psychedelics, ketamine, oxytocin, and agents modulating the orexin, endocannabinoid, and immune systems merits further study.
    MeSH term(s) Humans ; Anti-Anxiety Agents/therapeutic use ; Anxiety Disorders/drug therapy ; Anxiety Disorders/psychology ; Duloxetine Hydrochloride/therapeutic use ; Pregabalin/therapeutic use ; Treatment Outcome
    Chemical Substances Anti-Anxiety Agents ; Duloxetine Hydrochloride (9044SC542W) ; Pregabalin (55JG375S6M)
    Language English
    Publishing date 2023-05-15
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1080/14737175.2023.2211767
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A personal account of reducing and stopping antidepressant treatment.

    Baldwin, David S

    International clinical psychopharmacology

    2020  Volume 35, Issue 4, Page(s) 194–200

    Abstract: Having responded well to an antidepressant I was determined to continue treatment for 6 months, to increase the probability of a full and lasting recovery. My productivity at work and confidence in social situations increased and it seemed easier to talk ...

    Abstract Having responded well to an antidepressant I was determined to continue treatment for 6 months, to increase the probability of a full and lasting recovery. My productivity at work and confidence in social situations increased and it seemed easier to talk about emotional matters. Side effects became gradually less bothersome, though at times I was somewhat apathetic. Escitalopram may have helped to reduce long-standing back pain and niggly acoustic problems. Some symptoms appeared whilst I reduced the antidepressant dosage steadily: these were mild and resolved swiftly, but a few were quite puzzling. I hope this experience will enhance my understanding of the concerns of patients as they approach the end of a course of medication, and contribute to discussions of how to assess and manage symptoms that occur on and after stopping antidepressant treatment.
    MeSH term(s) Antidepressive Agents/adverse effects ; Antidepressive Agents/therapeutic use ; Citalopram/adverse effects ; Citalopram/therapeutic use ; Humans ; Male ; Withholding Treatment
    Chemical Substances Antidepressive Agents ; Citalopram (0DHU5B8D6V)
    Language English
    Publishing date 2020-04-23
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 632837-4
    ISSN 1473-5857 ; 0268-1315
    ISSN (online) 1473-5857
    ISSN 0268-1315
    DOI 10.1097/YIC.0000000000000315
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2162: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top